NASDAQ · PDSB
PDS Biotechnology Corporation
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
Loading market information…
NASDAQ · CALC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CalciMedica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CalciMedica, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$1.28. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CalciMedica, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 27, 2025 |
| -$0.34+29.17% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$2.500.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
$1.49+$0.07 (+4.56%)
RenovoRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.47% below the high.
$7.77-$0.24 (-3.0%)
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.26% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$1.74-$0.07 (-3.87%)
LAVA Therapeutics N.V.’s quoted price sits in the upper half of its reported 52-week range, 13.0% below the high.
$0.81-$0.03 (-3.13%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
